Senseonics backs FY25 revenue view $34M-$38M, consensus $35.54M

The company said, “Senseonics (SENS) continues to expect full-year 2025 global net revenue to be approximately $34-38 million as we continue to roll out Eversense 365 to U.S. patients. The full-year 2025 financial outlook assumes approximately doubling of our global patient base during 2025, with approximately one-third of revenue to be generated in the first half of 2025 and two-thirds of revenue to be generated in the second half of 2025. The financial outlook takes into consideration current assumptions regarding: refined visibility of the timeline and specifications for the regulatory approval and the plans for commercial transition to Eversense 365 outside the United States, projected plans with respect to spending on the DTC marketing campaign to generate leads, executing on other sales and marketing initiatives, anticipated utilization and impact of the patient assistance programs for Eversense 365, and continued progress with the transition of reimbursement from Eversense E3 to Eversense 365. Gross margins are expected to increase throughout 2025, with 2025 gross margins between 25 – 30% for the full year. Cash used in operations in 2025 is expected to be between $50-$60 million.”